 It could mean increased access to advanced forms of radiotherapy such as intensity modulated radiotherapy and stereotactic ablative radiotherapy.In July 2015 the independent cancer taskforce established by NHS England proposed reform of the fund, which the taskforce said was “no longer sustainable or desirable… in its current form”.Professor Karl Claxton, a health economist at the University of York, says that the fund should be scrapped because the money would be better used on 21,000 patients with heart, lung and gastro-intestinal diseases who are denied cost effective evidence based treatment, arguing that the principal beneficiary of the fund is 'big pharma'.